Table 1

Fasting and postmeal glycemic responses to treatment at Week 14

ParameterPlaceboMK-0941 dose (mg t.i.d. a.c.)
10203040
n111 to 114112 to 118113 to 117113 to 117113 to 118
A1C (%)
 Change from baseline−0.1 (−0.3 to 0.1)−0.6 (−0.8 to −0.4)−0.7 (−0.9 to −0.5)−0.9 (−1.1 to −0.7)−0.8 (−1.0 to −0.6)
 Change from placebo−0.5 (−0.8 to −0.2)*−0.6 (−0.9 to −0.4)*−0.8 (−1.1 to −0.5)*−0.8 (−1.0 to −0.5)*
FPG (mg/dL)
 Change from baseline−11.8 (−21.4 to −2.1)−10.0 (−19.9 to 0.0)−1.5 (−10.9 to 7.9)−21.1 (−30.9 to −11.2)−5.0 (−14.9 to 4.8)
 Change from placebo1.8 (−11.6 to 15.2)10.3 (−2.7 to 23.2)−9.3 (−22.6 to 4.0)6.7 (−6.6 to 20.0)
2-h PMG (mg/dL)
 Change from baseline−2.4 (−16.0 to 11.2)−39.0 (−52.9 to −25.1)−29.2 (−42.5 to −15.9)−37.4 (−51.2 to −23.6)−39.3 (−53.1 to −25.5)
 Change from placebo−36.6 (−55.6 to −17.5)*−26.7 (−45.4 to −8.1)**−35.0 (−54.0 to −16.0)*−36.9 (−55.9 to −17.9)*
  • Change from baseline or change from placebo data are expressed as LS mean change (95% CI).

  • *P ≤ 0.001 for the between-group difference relative to placebo.

  • **P ≤ 0.05 for the between-group difference relative to placebo.